Overview

Ascorbic Acid Treatment in CMT1A Trial (AATIC)

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
Charcot-Marie-Tooth type IA (CMT1A) is the most prevalent hereditary peripheral neuropathy. Demyelination of peripheral nerves is the hallmark of CMT1A. Ascorbic acid has been shown to have a favorable influence on myelination in in vitro studies and in a mouse model for CMT1A. We will study the efficacy and safety of ascorbic acid treatment in young patients with CMT1A.
Phase:
Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Treatments:
Ascorbic Acid
Vitamins